

Tetraphase enters into agreement with Biopharma firm in China

22 February 2018 | News

As per the agreement, Tetraphase will receive an initial upfront payment of \$7.0 million and may receive clinical and regulatory milestones of up to \$16.5 million as well as annual sales milestones of up to \$20.0 million.



Tetraphase Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, has entered into an exclusive licensing agreement with Everest Medicines Limited, a C-Bridge Capital-backed biopharmaceutical company based in China, to develop and commercialize eravacycline in mainland China, Taiwan, Hong Kong, Macau, South Korea, and Singapore.

Eravacycline is a novel, fully-synthetic fluorocycline antibiotic being developed for the treatment of complicated intra-abdominal infections (cIAI) and other serious infections, including those caused by multidrug-resistant (MDR) pathogens that have been highlighted as urgent public health threats by both the World Health Organization and the U.S. Centers for Disease Control & Prevention (CDC).

As per the agreement, Tetraphase will receive an initial upfront payment of \$7.0 million and may receive clinical and regulatory milestones of up to \$16.5 million as well as annual sales milestones of up to \$20.0 million.

Everest will be solely responsible for the development and commercialization of eravacycline. Tetraphase and Everest will establish a joint steering committee to review and oversee all of Everest's development and commercialization plans. Tetraphase will also be eligible to receive double digit tiered royalties on net sales of eravacycline.